SciELO - Scientific Electronic Library Online

 
vol.90Influence of Urbanistic Characteristics in the Level of Physical Activity in People Aged 18 to 65 of the Metropolitan Area Pamplona, Spain author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Española de Salud Pública

On-line version ISSN 2173-9110Print version ISSN 1135-5727

Abstract

ALFAGEME ROLDAN, Fernando; BERMEJO HERNANDO, Almudena; CALVO GONZALEZ, José Luís  and  MARQUES SANCHEZ, Pilar. Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks. Rev. Esp. Salud Publica [online]. 2016, vol.90, e30001.  Epub Apr 13, 2016. ISSN 2173-9110.

Background:

The objective was to evaluate the efficiency (relation between the cost and the results in health) of the treatments in psoriasis, seeking a higher quality of economic evaluations, consistency and transparency in these studies.

Methods:

We developed a model of economic evaluation in psoriasis collecting all the many direct and indirect costs of each treatment. The effectiveness indicator used was Psoriasis Area Severity Index [PASI 75] which is generally acceptable in studies of psoriasis. The effectiveness indicator was a PASI 75. Subsequently we calculated the Incremental Cost-Effectiveness Ratio (ICER) for the period of 12 weeks and PASI 75, ordering treatments by level of effectiveness at the expense of treatment costs.

Results:

The most cost effective treatment was methotrexate (ICER -7.5) followed by acitretin (ICER 29.5). The least cost has proved effective PUVA (ICER 4,651), followed by UVB narrow band (2,886.1).

Conclusions:

When taking into account both direct and indirect costs together with efficiency, methotrexate is the most cost effective treatment.

Keywords : Psoriasis; Cost-Effectiveness Analysis; Methotrexate; Adalimumab; Infliximab; Ustekinumab; Economic evaluation.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )